Table 2.

Sequencing analysis of pancreatic cancers using EUS-FNA/FNB

Year	References	Patientnumber	Cancertype	Samplingmethods	Analysismethods	Analysistarget	Success rate ofsequencing analysis	Detection rate ofactionable mutations
2013	Young et al. [41]	23	PDCA (18) Others (5)	FNA	Targeted seq	287 genes	100%	ND
2016	Valero et al. [55]	17	ND	FNA	Targeted seq with MB	409 genes	89.5%	23.5%
2016	Rodriguez et al. [56]	23	PDAC (15) Others (8)	FNA	RNA seq	85 genes	71.9%	ND
2016	Kameta et al. [35]	38	PDAC (27) Others (11)	FNA	Targeted seq	50 genes	100%	ND
2016	Gleeson et al. [41]	47	ND	FNA	Targeted seq	160 genes	61.7%	0%
2017	Lowery et al. [54]	52	PDAC (52)	FNA/FNB	Targeted seq	410 genes	ND	ND
2018	Larson et al. [48]	61	ND	FNA/FNB	Targeted seq	ND	67.2%	ND
2019	Elhanafi et al. [37]	167	ND	FNA/FNB	Targeted seq	47 genes	70.1%	ND
2019	Dreyer et al. [36]	41	PDAC (36) Others (5)	FNB	WGS	ND	72%	16%
2020	Ishizawa et al. [52]	26	PDAC (26)	FNA	Targeted seq	409 genes	100%	ND
2020	Park et al. [53]	190	PDAC (190)	FNA/FNB	Targeted seq	83 genes	57.4%	ND
2021	Kandel et al. [49]	50	PDAC (37) Others (13)	FNA/FNB	Targeted seq	ND	92%	ND
2021	Takano et al. [57]	58	PDAC (58)	FNA/FNB	Targeted seq with MB	50 genes	94.8%	22.4%
2021	Habib et al. [58]	59	PDAC (56) Others (3)	FNA	Targeted seq	9 genes	ND	ND
2021	Semaan et al. [59]	23	PDAC (23)	FNA	EpCAM-pulldown combinedwith MB WES	ND	100%	21.7%
2021	Carrara et al. [60]	33	PDAC (33)	FNB	Targeted seq	21 genes	97%	ND
2021	Kondo et al. [51]	22	ND	FNA	Targeted seq	324 genes	68.2%	ND
2022	Gan [50]	26	PDAC (26)	FNA/FNB	Targeted seq	ND	42–81%	ND
2022	Hisada et al. [61]	33	PDAC (31) Others (2)	FNB	Targeted seq	124 genes	57.1%	33.3%
2023	Ikeda et al. [62]	30	PDAC (30)	FNA/FNB	Targeted seq	124 genes	100%	ND

ND not described, EUS endoscopic ultrasound, FNA fine-needle aspiration, FNB fine-needle biopsy, PDAC pancreatic ductal adenocarcinoma, seq sequence, WGS whole-genome sequence, MB molecular barcodes, WES whole exome sequence